We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer Inc. announced today that the Phase 3 transthyretinopathy cardiomyopathy (ATTR-ACT) study in Tafamidis evaluates tafamyline treatment for transthyretin-induced cardiomyopathy in accordance with its primary endpoint